Your browser doesn't support javascript.
loading
Chimeric Antigen Receptor T Cells Therapy for the Treatment of B-lymphoblastic Hematologic Malignancy :A Rapid Health Technology Assessment / 中国药房
China Pharmacy ; (12): 2895-2900, 2021.
Artigo em Chinês | WPRIM | ID: wpr-906658
ABSTRACT
OBJECTIVE:To eval uate the effectivenesssafety and economy of chimeric antigen receptor T cellsCAR-T) therapy for the treatment of B-lymphoblastic hematologic malignancy ,and to provide evidence-based reference for clinical decision. METHODS:Rapid health technology assessment (HTA)was adopted. PubMed ,Embase,Cochrane Library ,CNKI,Wanfang databases and foreign HTA official websites were systematically searched during the inception-Mar. 20th,2021. After inclusion , data extraction and quality evaluation of literatures according to the inclusion and exclusion criteria ,descriptive analysis was performed for the effectivenesssafety and economy of CAR-T therapy for the treatment of B-lymphoblastic hematologic malignancy. RESULTS :A total of 2 HTA reports ,5 systematic reviews/Meta-analysis ,and 5 economics studies were included. In terms of effectivenessCAR-T therapy showed good efficacy in the treatment of B-lymphoblastic hematologic malignancy ;overall remission rate (ORR)of CAR-T therapy in the treatment of acute lymphoblastic leukemia was more than 63.5%,and the complete remission rate (CR)was 77.1%(95%CI:62.8%-87.1%);ORR of CAR-T therapy in the treatment of chronic lymphoblastic leukemia was 70.0%(95%CI:53.0%-80.0%),and the CR was 25.5%(95%CI:13.9%-42.1%);ORR of CAR-T therapy in the treatment of B-cell lymphoma was more than 44.4%. In terms of safety ,the incidence of cytokine release syndrome was more than 20% during the treatment of CAR-T therapy ,and 1/3 or more (9% believed in some studies )patients suffered from neurotoxicity ; the incidence of infection was 12.2%-33.3%,and the incidence of graft-versus-host disease was 23.4%(95%CI:8.6%-49.8%). In terms of economy ,most of the included studies believed that CAR-T therapy possessed economic advantages ,which were the results of evaluation in developed countries such as the United States and Japan. CONCLUSIONS :CAR-T,as a new product of treatment for hematological malignancy ,shows good effectiveness and low level of ADR ,which is basically controllable ;its economy needs to be further evaluated by relevant researches combined with domestic reality.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Avaliação de Tecnologias em Saúde / Estudo prognóstico Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2021 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Avaliação de Tecnologias em Saúde / Estudo prognóstico Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2021 Tipo de documento: Artigo